Positive attribute framing increases COVID-19 booster vaccine intention for unfamiliar vaccines.

Barnes, K. PhD[1], Colagiuri, B. PhD[1]

[1] *University of Sydney, Australia*

Corresponding Author:
Dr. Kirsten Barnes,
School of Psychology, A18
University of Sydney
NSW 2006
Australia
Email: kirsten.barnes@sydney.edu.au

Abstract

Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured booster intentions pre- and post-intervention in 1,222 UK-based participants. As hypothesised, vaccine familiarity significantly modulated the effect of framing. While positive framing was effective for the least familiar vaccine (i.e., Moderna), standard negative framing appeared to increase intentions for familiar vaccines (AstraZeneca/Pfizer), particularly among those with low baseline intentions. These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines – as is currently the case for millions of booster vaccines across the world. Positive framing of familiar vaccines, however, should be treated with caution.

Introduction

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) waning over time[1,2] and reduced for emerging variants[3,4], many countries are accelerating their COVID-19 booster programmes[5,6] . However, vaccine availability does not necessarily translate to vaccine acceptance[7], with the World Health Organization (WHO) recognising vaccine hesitancy as a global health threat[8]. Side effect apprehension is a primary factor driving hesitancy[9], with 90% of COVID-19 vaccine refusers fearing side effects more than COVID-19 itself[10]. Further, side effect severity from initial doses has been associated with booster vaccine hesitancy[11]. Reducing perceptions of side effects appears vital for increasing booster acceptance and reducing the global burden COVID-19.

The WHO[12] has suggested the framing of vaccine-relevant information[13] could provide a method of reducing negative perceptions. Positive attribute framing, where side effect information is framed in terms of the inverse incidence rate (e.g., "60% will ***not*** get a sore arm") as opposed to typical negative framing with the standard incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed consent is maintained due to statistical consistency across frames[14]. Third, there is preliminary evidence that positive attribute framing can improve vaccination attitudes in other settings. For example, one study on the influenza vaccine found positive attribute framing (hereafter positive framing) reduced the expectation and experience of side effects, increased perceived protection from influenza, and reduced distortions in the perception of side effect risk[15], with results replicated for other vaccine types[16].

The handful of studies examining framing on COVID-19 vaccine intention have produced mixed results[17-19]. However, those studies focused on vaccine-naïve individuals, did not employ attribute framing, and did not concern booster intentions. Further, those studies also either used fictitious COVID-19 vaccines[17,18] or did not name specific approved COVID-19 vaccines[19]. As such, participants either had limited knowledge of, or investment in, the framed vaccines. As the pandemic has progressed, media discourse[20,21] combined with direct and socially-observed experience of COVID-19 side effects[22], means it is essential to understand whether positive framing is effective for real-world vaccines where prior knowledge and experience exists. This is particularly important because there is reason to believe that prior knowledge regarding a given COVID-19 vaccine may moderate the strength of any positive framing effect.

Research has shown that greater relevance or belief in a treatment or issue decreases the efficacy of different forms of framing[23,24], including positive framing on perceptions of hypothetical vaccines[23,25]. The effect of positive framing on vaccine intention may therefore be limited to less familiar vaccines. Even if so, positive framing may still hold utility. New composition changes to COVID-19 booster vaccines have been recommended[26] and are currently being developed[27] to protect against emerging variants. Further, many booster programmes (e.g., in the United Kingdom) require switches from an experienced vaccine (e.g., AstraZeneca Vaxzevria) to a less familiar one (e.g., Moderna Spikevax). Positive framing may therefore be beneficial for increasing uptake for novel vaccines and switches to less familiar vaccines. Yet, because research on positive framing has largely focused on fictitious medications and patient scenarios[23,25,28-32], the extent to which familiarity moderates the effect of positive framing is currently unclear. Therefore, to understand the extent to which positive framing could be deployed to improve global vaccine uptake to combat

COVID-19, it is critical to test the efficacy of positive framing for genuine familiar and unfamiliar vaccines.

In this pre-registered study (aspredicted.org/53ph4.pdf), positive attribute framing was applied to side effects from genuine manufacturer Patient Information Leaflets (PILs) for the AstraZeneca, Pfizer, and Moderna vaccines and compared to standard negative wording. Participants were randomised to read positive or negatively framed PILs for the same vaccine they had previously received (either AstraZeneca/Pfizer), a familiar vaccine in the UK context (Pfizer/AstraZeneca), or an unfamiliar vaccine (Moderna). It was hypothesised that a) positive framing would increase booster intention, and b) the effect of positive framing would decrease with vaccine familiarity. Following previous research[14,28,33-35] secondary outcome variables concerning booster side effect severity, perceived risk, and booster acceptance, as well as prevalence judgments, were explored as potential mediators of the framing effect on vaccine intention (see Supplementary Materials 1).

Results

Overview

Participants (*N*=1,222) were recruited from the United Kingdom via Pureprofile, an international recruitment service, between 27th October and 8th November 2021. All were pre-screened (see Methods) with data removed on pre-registered quality control criteria (see Supplementary Materials 2). Only those who had received two doses of either the AstraZeneca or Pfizer COVID-19 vaccines were eligible to participate, with participants stratified by their previous vaccine type.

Participants from each stratum were subsequently randomised to one of six experimental conditions (2(Framing)*3(Familiarity) factorial design; see Figure 1). Baseline ratings were collected regarding primary and secondary outcome measures—all recorded on a 100-point VAS. The primary outcome was the participant's intention to receive a booster vaccine. Secondary outcomes were: 1) perceived booster side effect severity; 2) perceived booster risk; 3) booster acceptance. Wording of items can be found in Figure 1. Familiarity with the side effects of the AstraZeneca, Pfizer, and Moderna vaccines were additionally assessed (100-point VAS) to determine whether side effect knowledge corresponded with the predetermined factorial categories of vaccine Familiarity (i.e., Same > Familiar > Unfamiliar).



Figure 1: Overview of the experimental design, including the item wording for primary and secondary outcomes (*Nb*. analyses concerning secondary outcomes are contained in Supplementary Materials 1).

Framed side effect information was subsequently presented dependent on condition using genuine manufacturer PILs for the AstraZeneca, Pfizer, and Moderna vaccines, with side effects presented in standard EU verbal prevalence categories and frequency bands. Positive framing was applied to the frequency bands (for example see Figure 2; full wording and PILs presented as Supplementary Materials 3-4). To manipulate familiarity, participants were randomised to view PILs from the following conditions: 'Same' (PIL for the COVID-19 vaccine previously received: AstraZeneca-AstraZeneca|Pfizer-Pfizer); 'Familiar' (PIL for a common vaccine not previously received: Pfizer-AstraZeneca|AstraZeneca-Pfizer); 'Unfamiliar' (PIL for a less common vaccine in the UK: AstraZeneca-Moderna|Pfizer-Moderna). Familiarity was judged on UK data (22nd September 2021), where fewer Modena second doses (1.2 million) had been administered relative to the Pfizer and AstraZenca vaccine (19.4 and 24.0 million respectively)[36]. After timed PIL presentation of 2 minutes, all participants provided post-manipulation ratings for the primary and secondary outcomes (as above). Participants were then presented with 14 side effects from their assigned PIL and were required to: 1) assign each to a verbal prevalence category (i.e., very common, common, uncommon, rare, very rare); 2) estimate frequency of occurrence (number of people in 100,000 expected to experience the side effect (results in Supplementary Materials 1.4.1).

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may ***not be affected***)	 **Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may ***not be affected***)	 **Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

Figure 2: Positive and negative wording used to frame common and uncommon side effects (wording for all prevalence categories can be found in Supplementary Materials 3)

Descriptive Statistics

Sample demographics

Information regarding participant location, age, education, and employment can be found in Figure 2a-b. Participants were 52.5 years of age on average (range=18-95). They resided across most postal areas in the UK, with the largest proportion from London district (*N*= 53), Birmingham (*N*=35), and Belfast (*N*=34). Only Harrogate, and the Orkney and Shetland Islands were not represented. The largest proportion of respondents identified as British (*N*=1,064; 87%), female (*N*=706; 58%), had completed undergraduate-level education (*N*=413; 34%), and were in full-time employment (*N*=407; 33%). Descriptive statistics for the full sample, and by condition, are presented as Supplementary Materials 5-6.

155

156 ***COVID-19 exposure and vaccine history***

157 Most participants (*N*=1,074; 88%) had not personally been infected with COVID-19,
158 while 565 (46%) reported infections among family and close friends. On average, participants
159 had their last COVID-19 vaccine 4.8 months ago. The largest proportion reported not
160 experiencing side effects to either dose (*N*=579; 47%). Of those who did, the first dose was most
161 associated with severe side effects (*N*=372; 30%).



Figure 3: Demographic Information, where 3a plots the frequency of participants from each postal area of the UK against the vaccination rates reported by the UK government on the 3rd November (the final week of data collection) and 3b depicts education and employment categories, and age range, across experimental conditions. *Nb.* 6 participants, 0.5% of the sample, are not represented in 3a due to not providing a valid postal code.

Primary Analysis

Knowledge of vaccine side effects mirrors categorical levels of the Familiarity factor

To determine whether side effect familiarity corresponded with the predetermined factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way ANOVA (with Greenhouse–Geisser correction) was run on side effect familiarity ratings collected for the three vaccine types prior to the experimental manipulation. A robust main effect of Familiarity was observed ($F(1.86, 2272.18)=659.17$, $p<.001$, $\eta_p^2=.35$). Awareness of side effects increased with Familiarity; being higher for the Same vs. Familiar vaccine ($t(1221)=14.11$, $p<.001$, Cohen's $d_z=.40$), and for the Familiar vs. Unfamiliar vaccine ($t(1221)=23.97$, $p<.001$, Cohen's $d_z=.69$). Mean differences are presented in Figure 4e.

Baseline vaccine intention

A 2(Framing)*3(Familiarity) ANOVA was conducted on Baseline Booster Intention scores to assess the presence of between-group differences. Baseline Booster Intention was anticipated to be high across conditions (see pre-registration), which was confirmed in the present sample ($M=78.36$ (/100-point VAS), $SD=31.65$; range:0-100). However, an unanticipated significant effect of Familiarity was observed($F(2, 1216)=49.51$, $p<.0001$, $\eta_p^2=.075$). This effect reached significance for the orthogonal contrast comparing the Same vs. Other (i.e., combined Familiar and Unfamiliar) vaccine types ($F(1, 1216)=96.51$, $p<.0001$, $\eta_p^2=.074$), but not for the Familiar vs. Unfamiliar comparison ($F(1, 1216)=2.42$, $p=.120$, $\eta_p^2=.002$), indicating higher intentions for previously experienced vaccines.

Effect of Framing and Familiarity on the intention to be vaccinated

The pre-registered primary analysis plan was a 2(Framing: Positive vs. Negative)*3 (Familiarity: Same, Familiar, Unfamiliar) factorial ANCOVA, with Baseline Booster Intention for the vaccine presented in the participant's assigned PIL as the covariate, and Post-Manipulation Booster Intention the outcome. However, the fact that Baseline Intention unexpectedly differed systematically with Familiarity meant that including it as a covariate without including its interactions with the manipulated variables (Framing and Familiarity) would violate the assumptions of ANCOVA[37]. To address this, we extended the model to include the interactions between Baseline Booster Intention and Framing and Familiarity in all analyses, as recommended elsewhere[38]. Pre-specified orthogonal contrasts for Familiarity were: Contrast1 (Same vs. Other [Familiar and Unfamiliar combined]); Contrast2 (Familiar vs. Unfamiliar). A Framing*Familiarity interaction was hypothesised, with the effect of Framing (increased Booster Intention following Positive vs. Negative framing) reducing with increased Familiarity.

Main effects analysis revealed the anticipated Framing*Familiarity interaction ($F(2, 1210)=10.75$, $p<.0001$, $\eta_p^2=.018$). Specifically, Framing interacted with Contrast1 (Same vs. Other: $F(1, 1210)=5.07$, $p=.025$, $\eta_p^2=.004$) and Contrast2 (Familiar vs. Unfamiliar: $F(1, 1210)=16.46$, $p=.0001$, $\eta_p^2=.013$). As demonstrated in Figure 4a, this pattern of results was driven by Positive Framing increasing Booster Intention for the Unfamiliar vaccine. However, this was superseded by a three-way interaction with Baseline Booster Intention ($F(2, 1210)=7.65$, $p=.0005$, $\eta_p^2=.013$), represented at both Contrasts (Baseline*Framing*Contrast1: $F(1, 1210)=4.39$, $p=.036$, $\eta_p^2=.004$ | Baseline*Framing*Contrast2: $F(1, 1210)=11.19$, $p=.0008$, $\eta_p^2=.009$). Figure 4b depicts this interaction. Positive Framing had limited efficacy at high levels of Baseline Intention across Conditions but took effect for the Unfamiliar Vaccine when model

estimated Baseline Intention scores were lower than ~80/100. At very low levels of Baseline Intention (i.e., VAS=0), model predicted Booster Intention Post-Manipulation increased from *M*=19.09 (*SEM*=2.76, 95% CIs[13.68, 24.50]) for the Negative Frame, to *M*=35.11 (*SEM*=2.77, 95% CIs[29.68, 40.50]) for the Positive Frame. Full model output is included as Supplementary Materials 7. We note that the same interaction between Framing and Familiarity was observed in the planned but invalid model excluding the interaction between these factors and Baseline Booster Intention (see Supplementary Materials 8).

The effect of Framing on vaccine switches

Analyses were performed to investigate the effect of framing on pre-registered and realistic vaccine switches occurring as part of the UK's booster programme. Specifically, those without medical exemption, who previously received the AstraZeneca vaccine will be required to switch to Pfizer or Moderna, while those who received Pfizer may be required to switch to Moderna.

First, previous vaccine type (AstraZeneca/Pfizer) was entered as a factor in the ANCOVA model above to check for interactions with Framing, Familiarity, and Baseline Booster Intention. While there was a main effect of previous vaccine type ($F(1, 1198)=6.36$, $p=.012$, $\eta_p^2=.005$), with those receiving AstraZeneca reporting increased Booster Intention (*M*=80.83, *SEM*= 0.74, 95% CIs [79.37, 82.29]) compared to Pfizer (*M*=78.01, *SEM*= 0.74, 95% CIs [76.57, 79.46]), there were no two- or three-way interactions with Framing or Familiarity (all *ps*>.05; see Supplementary Materials 9).

Previous vaccine: AstraZeneca

Representative of a switch from AstraZeneca to Pfizer or Moderna, a 2(Framing)*2(Familiarity: Familiar (Pfizer), Unfamiliar (Moderna)) ANCOVA (modelling interactions between covariate and factors), was conducted among those who had previously received the AstraZeneca vaccine (N=410). A three-way Framing*Familiarity*Baseline Intention interaction was observed ($F(1, 402)=11.38$, $p=.0008$, $\eta_p^2=.028$). As demonstrated in Figure 4c, in the case of the Unfamiliar vaccine (Moderna) Booster Intention was increased in the Positive Frame at low levels of Baseline Booster Intention. However, the inverse of this pattern was observed for the Familiar vaccine (Pfizer), where Positive Framing decreased Booster Intention at low levels of Baseline Intention.

Previous vaccine: Pfizer

Representative of a switch from Pfizer to Moderna, a one-way ANCOVA investigating the effect of framing on the perception of the Unfamiliar (i.e., Moderna) PIL was performed on the data of those who had previously received the Pfizer vaccine (N=202). There was a main effect of Framing ($F(1, 198)=3.98$, $p=.048$, $\eta_p^2=.020$), but no statistically significant Baseline Booster Intention*Framing interaction ($F(1, 198)=1.80$, $p=.181$, $\eta_p^2=.009$). However, as demonstrated in Figure 4d, slopes for the Positive and Negative Frame converged at high levels of Baseline Booster Intention.



Figure 4: Model estimated mean differences in the primary outcome (Booster Intention), depicted for the whole sample (4a and 4b), and for realistic switches occurring as part of the UK booster programme (4c and 4d). 4e presents data demonstrating that side effect familiarity ratings scaled with the factorial levels of Vaccine Familiarity. All error bars represent ± 1SEM.

Discussion

Message framing has been suggested as a potential intervention to increase COVID-19 vaccine uptake[12]. We examined the effect of positive and negative attribute framing of side effect information on booster intentions for three genuine COVID-19 vaccines varying in familiarity. Positive framing successfully increased booster intention for the unfamiliar vaccine (i.e.,

266 Moderna), but reduced intention for the vaccine previously received, as well as for a switch to
267 Pfizer among those previously receiving AstraZeneca. In all cases, effects were strongest at low
268 baseline booster intentions. Increasing booster acceptance among those with low intentions is of
269 substantial importance in protecting against infection from, and transmission of, COVID-19
270 viruses. Critically, our data suggest that any intervention intending to employ attribute framing
271 should be carefully tailored to match the framed information (positive vs. negative wording) with
272 vaccine familiarity. Specifically, positive framing appears to have significant potential in
273 situations where a novel vaccine or composition changes are being introduced[26,27]. By contrast,
274 positive framing may actually be harmful when the vaccine is familiar.
275
276 The effect of positive attribute framing on booster intentions for the Unfamiliar vaccine is
277 consistent with medical decision-making research. In these studies, framed information has
278 typically been presented regarding fictitious medications and patient scenarios[23,25,28-32]. When
279 employing real treatments, data has been collected from samples where participants were
280 completely[15,39] or largely[40] naïve to the framed treatment, or where prior treatment experience
281 was not assessed[16,41]. The current data thereby provide new insights into the effect of framing.
282 Under conditions directly relevant to the COVID-19 pandemic (i.e., for real vaccines, at high
283 levels of public involvement), the benefit of positive attribute framing was found to wane, or be
284 reversed, as familiarity and prior experience with the framed vaccine increased. As such, calls
285 for all PILs to employ positive framing as standard (e.g.,[28,42]) appear premature. Instead, negative
286 framing, the standard form for communicating side effect information within the European
287 Union, appears beneficial when treatments are well known.
288

289 The reduced efficacy of positive framing with increased vaccine familiarity could be
290 explained by a current theory of attribute framing that posits an interaction between familiarity (a
291 manifestation of psychological distance) and the valence of the message surrounding a given
292 attribute or event (e.g., the experience of vaccine side effects). At closer psychological distances
293 (e.g., for vaccines that are more familiar and more likely to be received), negatively framed
294 information has been shown to be more persuasive[43]. Further experimental research is needed to
295 test this theory, while considering alternative explanations, such as the role of potential backfire
296 effects in persuasive or corrective messaging. Such effects are known to impact attitudes
297 surrounding the COVID-19 pandemic[44] and have been demonstrated to lower intentions for other
298 vaccine types at high levels of concern[45]. However, when assessed in conjunction, current results
299 highlight the fact that any intervention that strives to apply positive framing across all vaccine
300 types, irrespective of familiarity, should be treated with caution.
301
302 The psychological mechanisms underlying the effect of positive framing on booster
303 intentions remain unclear. We measured secondary variables as potential mediators. However,
304 results did not mirror those obtained for the primary outcome – booster intention (see
305 Supplementary Materials 1). While changes in secondary variables (side effect severity and
306 booster acceptance) were observed with framing, post-hoc analysis (see Supplementary
307 Materials 10) plotting the Familiarity*Framing*Baseline interaction for those who had high vs.
308 low baseline booster intent, suggested that these framing-induced changes largely occurred
309 among those with high vaccine intention at baseline. As these participants also showed limited
310 effect of framing on their behavioural intention to be vaccinated, the relationship between
311 booster intention and our secondary predictors appears orthogonal. Investigation of other factors

312 combined with qualitative research may be better positioned to identify the driving factors
313 behind the effect of framing on COVID-19 booster intentions. Further, we note that, consistent
314 with previous reports[35,46-49], prevalence judgements were poor (<~35% accuracy; Supplementary
315 Materials 1.4). This appeared exacerbated among those receiving positive framing, but again did
316 not differ by familiarity. As side effects differed by PIL, the current study was designed only to
317 test for general inaccuracies in side effect representation and not systematic over- or under-
318 estimation. Experimental studies are therefore needed to assess precisely how any inaccuracies
319 associated with positively framed COVID-19 vaccine information manifest.
320
321 The primary strength of the present study is the application of attribute framing to real
322 COVID-19 vaccine information. The PILs employed here are displayed on government and NHS
323 websites in the UK, forming a primary official source of information regarding COVID-19
324 vaccination. Our findings therefore have real-world implications, demonstrating that the wording
325 of PILs can directly impact the intention to receive a booster vaccine among individuals for
326 whom this decision is both directly relevant and imminent. There are of course some limitations
327 worth noting including the collection of cross-sectional data that limits an assessment of the
328 durability of the framing effect, as well as a sample located within a single country. Given global
329 differences in booster policy, cross-cultural replication of results is required to ensure results are
330 not contextually limited to the UK. While vaccine intention has been demonstrated to be a strong
331 predictor of vaccine uptake (e.g.,[50-52]), including for COVID-19 vaccination[53], we do not assume
332 that the two are synonymous[54]. While beyond the scope of the present study, we recommend that
333 future research incorporate longitudinal designs where the rate of conversion from intention to
334 vaccine uptake can be tracked. Further, present results are specific to booster intentions among

335 those already vaccinated. While side effect apprehension has been associated with hesitancy
336 regarding COVID-19 vaccination[9] and booster vaccination[11], whether a similar pattern of results
337 would hold among those who have never been vaccinated is unknown.
338
339 In summary, the present study demonstrates that the ability of positive framing to
340 successfully increase booster intention for genuine COVID-19 vaccines is critically moderated
341 by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar
342 vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide
343 novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such,
344 we recommend that if positive attribute framing is to be employed, close attention must be paid
345 to the type of treatment being framed as well as the likely recipients of the framed information.
346 Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable
347 of improving uptake of COVID-19 vaccines when switches or new developments require
348 individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes
349 globally.
350

351 Methods

352 Recruitment and Sample

353 Recruitment took place in the initial weeks of the UK booster programme (27th October -
354 8th November 2021). Figure 3a provides a summary of the number of boosters administered in
355 the UK at the time of data collection. The sample was obtained from Pureprofile, an ISO-
356 certified panel provider for online research, and balanced on national quotas for age, gender, and
357 region. All potential participants were screened using the following inclusion criteria: 18 years of

358 age or older, currently residing in the UK, self-reported English fluency, previously received two
359 doses of either the Pfizer or the AstraZeneca COVID-19 vaccines (no other combination), not
360 having received a third COVID-19 booster vaccine, and no known medical reason (e.g., allergy)
361 prohibiting potential administration of the Pfizer, AstraZeneca, or Moderna COVID-19 vaccines.
362 After screening, 1896 participants provided electronic consent and 1459 completed the
363 experiment. To reduce statistical noise due to random and inconsistent responding, 237
364 completing participants were removed based on pre-registered quality control criteria (see
365 Supplementary Materials 2). The experiment was approved by the University of Sydney Human
366 Research Ethics Committee. All completing participants were provided with an electronic
367 debrief at the end of the survey and were paid £3.50 for a ~15-minute survey.
368
369 **Data Collection and Procedure**
370 Cross-sectional data were collected online via Qualtrics, with the survey accessible to
371 personal computer, tablet, and smartphone. The 'force response' option was used to ensure
372 complete cases for all outcome variables. Participants completed the survey in one sitting and
373 were not able to return to the study URL. After pre-screening, those meeting the inclusion
374 criteria were provided with a participant information statement detailing the aims of the study
375 and gave their digital informed consent. Those not meeting these criteria were directed away
376 from the survey.
377
378 Participants completed demographic items and identified which COVID-19 vaccine they
379 had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental
380 groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set

381 to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100
382 from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas
383 on survey completion but does not account for participants currently in the experimental
384 pipeline, the final sample contained 22 more participants than projected. Statistical analysis did
385 not take place until after exclusions had been made and all quotas were closed.
386
387 After randomisation, participants responded to items concerning the number of months
388 since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines.
389 For each vaccine type, participants then rated their booster intention, perceived booster side
390 effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and
391 anxiety). Responses made to the vaccine type that matched with the experimental condition to
392 which the participant had been assigned were employed as baseline measures. Responses to all
393 other vaccine types were recorded for use in a concurrent, but separate, pre-registered study
394 (#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side
395 effect information were then displayed for two minutes, using a timer embedded in the survey.
396 Participants could not proceed until this time had elapsed. Post-manipulation booster intention,
397 perceived booster side effect severity, perceived booster risk, and booster acceptance were then
398 recorded. Finally, fourteen side effects described in the PILs were presented, with participants
399 required to assign each to a verbal prevalence descriptor (very common, common, uncommon,
400 rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would
401 experience the side effect. On completing the survey, all participants were provided with an
402 electronic debrief for download and URLs to the UK government landing page where the
403 original PILs for the vaccines used in the study could be found.

Several additional items concerning general COVID-19 booster intentions, perceived risk of previous COVID-19 vaccines, specific COVD-19 vaccination side effects, general perceptions of COVID-19 and COVID-19 vaccinations, and severity of previous COVID-19 infection, were included in the survey for use in a separate pre-registered study (for information see: #78370; aspredicted.org/8e6af.pdf).

Survey Materials

Demographic information

Participants responded to items concerning their age, gender, ethnicity, highest level of education and employment status, and geographic region (postal area code). Exact wording can be found in the Demographic Information section, Supplementary Materials 5.

Previous exposure to COVID-19

Items were employed to capture personal exposure to COVID-19, as well as exposure through close friends and family. Item wording (*To your knowledge, are you, or have you been, infected with COVID-19? / To your knowledge, have any of your close family members or friends been infected with COVID-19?)* was taken from the WHO BeSD documentation[12].

Previous COVID-19 vaccination history

Previous COVID-19 vaccine (Pfizer/AstraZeneca) was recorded as a forced-choice option. Participants indicated the number of months since their last COVID-19 vaccine, and

426 whether their most severe side effects occurred to their first dose, second dose, whether they
427 were equal across doses, or not experienced at all.
428
429 ***Familiarity with COVID-19 vaccine side effects***
430 For the three framed vaccines, participants were asked to rate their "*familiarity with the*
431 *potential side effects*" on a 100-point VAS, with anchor labels (*'not at all familiar'* / *'extremely*
432 *familiar'*) positioned to the left and right of the scale. Those who had not heard of the vaccine
433 were asked to check a separate '*not heard of vaccine'* box but received a score of zero (*not at all*
434 *familiar*). This response-type was used to exclude inconsistent responders (see Supplementary
435 Materials 2).
436
437 ***Baseline measures: COVID-19 vaccine perceptions***
438 Four items were used as baseline measures. All were rated on a 100-point VAS. For each
439 of the three vaccines, participants responded to questions concerning: 1) booster intention *'If you*
440 *were offered* [vaccine type] *as a booster vaccine to maintain protection against COVID-19*
441 *viruses, how likely would you be to accept?'* (labels: *'definitely would not accept vaccine'* vs.
442 *'definitely would accept vaccine'*); 2) perceived booster side effect severity *'Overall, how severe*
443 *do you think the* [vaccine type] *side effects are?'* (labels: *'not at all severe'* vs. *'extremely*
444 *severe'*); 3) perceived booster risk *'What do you think the risk to your health would be if you*
445 *received* [vaccine type] *as a booster vaccine, bearing in mind its side effects?'* (labels:
446 *'extremely low risk'* vs. *'extremely high risk'*); 4) booster switch perceptions *'Imagine that*
447 *switching to the* [vaccine type] *vaccine was your only option for a booster. Please rate how*
448 *satisfied, happy, and anxious, you would be with this outcome'* (labels: *'not at all'* vs.

449 *'extremely'*). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score
450 of 0 – 100. Where the vaccine type was the same as that previously received by the participant,
451 wording was changed from 'switching to' to 'continuing with'. Wording of 1 – 3 was adapted
452 from previous research[35].
453
454 ***Patient Information Leaflets (PILs): Experimental manipulation***
455 Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include
456 the manufacturer's description of each vaccine, what it is used for, and critically, the possible
457 side effects resulting from administration. Side effects were retained in their original form and
458 order. For both the negatively and positively framed PILs, verbal descriptors were in keeping
459 with those published by the manufacturer (i.e., very common, common, uncommon, rare, very
460 rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs
461 was also identical to that of the manufacturer. However, this was inverted in the positively
462 framed PILs to stress the number of individuals *not* affected (e.g., "Common (90 in 100 or more
463 people may *not be affected*)"). As multi-modal forms of side effect presentation (e.g., written,
464 pictorial, verbal) may elicit larger framing effects[14], and numeracy is less likely to moderate the
465 effect of attribute framing for graphical presentations[55], positive PILs additionally included a
466 graphical representation of side effect risk to enhance the manipulation. For an example of the
467 wording used to frame side effects see Figure 2.
468
469 ***Post-manipulation measures: COVID-19 vaccine perceptions***

Participants responded to the four vaccine perception items listed above under Baseline Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but only in relation to the vaccine type outlined in the PIL to which they were assigned.

Post-manipulation side effect perceptions

To determine whether positive framing augments the perception of side effect occurrence relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of these were associated with concrete prevalence brackets in the original PILs, while the remaining three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL publication). For each side effect, participants were required to identify the correct verbal descriptor (very common, common, uncommon, rare, very rare): "*based on the information that you read, how common do you think* [side effect] *is?"* (forced-choice answer). They were then asked, "*In 100,000 people, how many do you think would experience* [side effect] *if they received a* [framed vaccine name] *booster vaccine?"* (free-response, limited to numbers at up to 10 decimal places). The three 'unknown' side effects were analysed separately to determine the effect of framing when prevalence rates are not provided.

Statistical Analysis

Statistical analysis was performed using R (version 4.1.1). Statistical analyses were a combination of ANCOVAs (where baseline measures were available) or ANOVAs, reported with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical significance. Sample size (estimated N=1200) was calculated based on an *a priori* power analysis (95% power, alpha=.05, effect size f^2=0.02) for a separate study run concurrently that contained

more predictor variables (*N*=9), and therefore required more power, than the study presented here (further details contained in the study pre-registration form). An effect size for attribute framing was additionally derived from previous research (average effect size $r = 0.175$)[14]. An *a priori* power analysis based on this effect size required a total of 491 participants, providing reassurance that the projected sample size for the study above provided ample power to detect an effect of framing in the present study.

Acknowledgements

Sources of Funding: This research was supported by Australian Research Council grants DP180102061 and DP200101748. The funding body had no involvement in study design, analysis, interpretation, writing, or the decision to submit the present article for publication.

Data Availability: The code and raw data necessary to replicate the reported analysis is available through the Open Science Framework repository (means/SEMs needed to reproduce the analysis figures are included with the raw data):
https://osf.io/d5cvn/?view_only=500c83d90bb9416796e464108ad2fc41

Author contributions: KB and BC conceived the experimental design. KB was responsible for collecting and analysing the data. KB wrote the first draft of the article. BC edited and contributed to the final version.

References

516 1 Andrews, N. *et al.* Vaccine effectiveness and duration of protection of Comirnaty,
517 Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint at:
518 https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 (2021).
519 2 Goldberg, Y. *et al.* Waning immunity of the BNT162b2 vaccine: A nationwide study
520 from Israel. Preprint at:
521 https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1(2021).
522 3 Cele, S. *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer
523 BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at:
524 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855.2/ (2021).
525 4 Basile, K. *et al.* Improved neutralization of the SARS-CoV-2 Omicron variant after
526 Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. Preprint at:
527 https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1.abstract (2021).
528 5 Mahase, E. Covid-19 booster vaccines: What we know and who's doing what. *BMJ* **374**,
529 n2082 (2021).
530 6 *All adults to be offered COVID-19 boosters by end of January* (gov.uk, 2021);
531 https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-
532 of-january
533 7 MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**,
534 4161-4164 (2015).
535 8 *Ten threats to global health in 2019* (World Health Organisation, 2019);
536 https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
537 9 Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-
538 income countries. *Nature Medicine* **27**, 1385-1394 (2021).
539 10 *Why won't Americans get vaccinated?* (Economist/YouGov poll, 2021);
540 https://today.yougov.com/topics/politics/articles-reports/2021/07/15/why-wont-
541 americans-get-vaccinated-poll-data
542 11 Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19
543 Vaccine Dose in Poland. *Vaccines* **9**, 1286 (2021).
544 12 *World Health Organization. Data for action: achieving high uptake of COVID-19*
545 *vaccines: gathering and using data on the behavioural and social drivers of vaccination:*
546 *a guidebook for immunization programmes and implementing partners: interim*

547 *guidance, 1 April 2021.* (World Health Organization, 2021);
548 https://apps.who.int/iris/handle/10665/340645
549 13 Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A
550 Typology and Critical Analysis of Framing Effects. *Organizational Behavior and Human*
551 *Decision Processes* **76**, 149-188 (1998).
552 14 Barnes, K. *et al.* Can Positive Framing Reduce Nocebo Side Effects? Current Evidence
553 and Recommendation for Future Research. *Frontiers in Pharmacology* **10**, 167 (2019).
554 15 O'Connor, A. M., Pennie, R. A. & Dales, R. E. Framing effects on expectations,
555 decisions, and side effects experienced: The case of influenza immunization. *Journal of*
556 *Clinical Epidemiology* **49**, 1271-1276 (1996).
557 16 Bigman, C. A., Cappella, J. N. & Hornik, R. C. Effective or ineffective: Attribute framing
558 and the human papillomavirus (HPV) vaccine. *Patient Education and Counseling* **81**,
559 S70-S76 (2010).
560 17 Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A.
561 Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the
562 United States and the United Kingdom: A Randomized Controlled Trial. Preprint at:
563 https://www.medrxiv.org/content/10.1101/2021.10.12.21264877v2 (2021).
564 18 Chen, T., Dai, M., Xia, S. & Zhou, Y. Do Messages Matter? Investigating the Combined
565 Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19
566 Vaccination Attitudes and Intention. *Health Communication*, 1-8 (2021).
567 19 Huang, Y. & Liu, W. Promoting COVID-19 Vaccination: The Interplay of Message
568 Framing, Psychological Uncertainty, and Public Agency as a Message Source. *Science*
569 *Communication* **44**, 3-29 (2021).
570 20 Lentzen, M.-P. *et al.* A retrospective analysis of social media posts pertaining to COVID-
571 19 vaccination side effects. *Vaccine* **40**, 43-51 (2022).
572 21 Jamison, A. M. *et al.* Vaccine-related advertising in the Facebook Ad Archive. *Vaccine*
573 **38**, 512-520 (2020).
574 22 Ndwandwe, D. & Wiysonge, C. S. COVID-19 vaccines. *Current Opinion in Immunology*
575 **71**, 111-116 (2021).

576 23 Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant
577 Immunization: The Influence of Involvement. *Health Education & Behavior* **27**, 82-95
578 (2000).
579 24 Benjamin, D., Por, H.-H. & Budescu, D. Climate Change Versus Global Warming: Who
580 Is Susceptible to the Framing of Climate Change? *Environment and Behavior* **49**, 745-
581 770 (2016).
582 25 Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within
583 messages to change vaccination behavior. *Journal of Communication in Healthcare* **8**,
584 45-54 (2015).
585 26 *Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron*
586 *SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine*
587 *Composition (TAG-CO-VAC)* (World Health Organization, 2022);
588 https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-
589 the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-
590 advisory-group-on-covid-19-vaccine-composition
591 27 Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by
592 spring (*The Washington Post,* 2022);
593 https://www.washingtonpost.com/business/2022/01/11/pfizer-omicron-specific-vaccine/
594 28 Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two
595 Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A
596 Randomised Trial of 16- to 75-Year-Olds in England. *Drug Safety* **43**, 1011-1022 (2020).
597 29 Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in
598 Health Decisions. *Organizational Behavior and Human Decision Processes* **85**, 382-399
599 (2001).
600 30 Levin, I. P., Schnittjer, S. K. & Thee, S. L. Information framing effects in social and
601 personal decisions. *Journal of Experimental Social Psychology* **24**, 520-529 (1988).
602 31 Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of
603 recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in
604 hypothetical patient scenarios. *Breast Cancer Research and Treatment* **60**, 9-14 (2000).
605 32 Marteau, T. M. Framing of information: Its influence upon decisions of doctors and
606 patients. *British Journal of Social Psychology* **28**, 89-94 (1989).

607 33 Webster, R. K. & Rubin, G. J. Predicting Expectations of Side-Effects for Those Which
608 Are Warned Versus Not Warned About in Patient Information Leaflets. *Ann Behav Med*
609 **12**, 1253–1261 (2021).
610 34 Herber, O. R., Gies, V., Schwappach, D., Thürmann, P. & Wilm, S. Patient information
611 leaflets: informing or frightening? A focus group study exploring patients' emotional
612 reactions and subsequent behavior towards package leaflets of commonly prescribed
613 medications in family practices. *BMC Family Practice* **15**, 163 (2014).
614 35 Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:
615 An empirical evaluation of EU recommended terminology. *Psychology, Health &*
616 *Medicine* **8**, 251-263 (2003).
617 36 *Research and analysis: Coronavirus vaccine - weekly summary of Yellow Card reporting*
618 (gov.uk, 2021); https://www.gov.uk/government/publications/coronavirus-covid-19-
619 vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
620 37 Myers, J. L. & Well, A. D. *Research design and statistical analysis, 2nd ed*. (Lawrence
621 Erlbaum Associates Publishers, 2003).
622 38 Cardinal, R. N. & Aitken, M. R. F. *ANOVA for the behavioural sciences researcher*.
623 (Lawrence Erlbaum Associates Publishers, 2006).
624 39 Llewellyn-Thomas, H. A., McGreal, M. J. & Thiel, E. C. Cancer Patients' Decision
625 Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-
626 term Toxicity and Long-term Survival. *Medical Decision Making* **15**, 4-12 (1995).
627 40 Ferguson, E. & Gallagher, L. Message framing with respect to decisions about
628 vaccination: The roles of frame valence, frame method and perceived risk. *British*
629 *Journal of Psychology* **98**, 667-680 (2007).
630 41 Jasper, J. D., Goel, R., Einarson, A., Gallo, M. & Koren, G. Effects of framing on
631 teratogenic risk perception in pregnant women. *The Lancet* **358**, 1237-1238 (2001).
632 42 Webster, R. K., Weinman, J. & Rubin, G. J. Explaining all without causing unnecessary
633 harm: Is there scope for positively framing medical risk information? *Patient Education*
634 *and Counseling* **102**, 602-603 (2019).
635 43 Freling, T. H., Vincent, L. H. & Henard, D. H. When not to accentuate the positive: Re-
636 examining valence effects in attribute framing. *Organizational Behavior and Human*
637 *Decision Processes* **124**, 95-109 (2014).

638 44 Dan, V. & Dixon, G. N. Fighting the Infodemic on Two Fronts: Reducing False Beliefs
639 Without Increasing Polarization. *Science Communication* **43**, 674-682 (2021).
640 45 Nyhan, B. & Reifler, J. Does correcting myths about the flu vaccine work? An
641 experimental evaluation of the effects of corrective information. *Vaccine* **33**, 459-464
642 (2015).
643 46 Webster, R. K., Weinman, J. & Rubin, G. J. People's Understanding of Verbal Risk
644 Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to
645 65-Year-Olds in England. *Drug Safety* **40**, 743-754 (2017).
646 47 Berry, D. C., Knapp, P. R. & Raynor, T. Is 15 per cent very common? Informing people
647 about the risks of medication side effects. *International Journal of Pharmacy Practice*
648 **10**, 145-151 (2002).
649 48 Berry, D. C., Raynor, D. K., Knapp, P. & Bersellini, E. Patients' Understanding of Risk
650 Associated with Medication Use. *Drug Safety* **26**, 1-11 (2003).
651 49 Knapp, P. *et al.* Communicating the Risk of Side Effects to Patients. *Drug Safety* **32**, 837-
652 849 (2009).
653 50 Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in
654 Young Adult Women: Comparing the Health Belief Model and Theory of Planned
655 Behavior. *Annals of Behavioral Medicine* **44**, 171-180 (2012).
656 51 Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get
657 vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel.
658 *Vaccine* **32**, 6986-6991 (2014).
659 52 Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:
660 Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual
661 Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).
662 53 Jensen, U., Ayers, S. & Koskan, A. *Video-based messages to reduce COVID-19 vaccine*
663 *hesitancy and nudge uptake*. Preprint at: https://psyarxiv.com/df9qw/ (2021).
664 54 Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.
665 *European Review of Social Psychology* **12**, 1-36 (2002).
666 55 Kreiner, H. & Gamliel, E. Are highly numerate individuals invulnerable to attribute
667 framing bias? Comparing numerically and graphically represented attribute framing.
668 *European Journal of Social Psychology* **47**, 775-782 (2017).


Pre-Screened Participants
(Total N = 1222)
Previous Vaccine:
AstraZeneca
(AZ = 615)
Previous Vaccine:
Pfizer
(Pf = 607)
PIL: Same as Previous Vaccine
(AZ = 205 / Pf = 205)
PIL: Different / Familiar Vaccine
(AZ = 204 / Pf = 200)
PIL: Different / Unfamiliar Vaccine
(AZ = 206 / Pf = 202)
Positive
(AZ = 103 / Pf = 104)
Negative
(AZ = 102 / Pf = 101)
Positive
(AZ = 101 / Pf = 100)
Negative
(AZ = 103 / Pf = 100)
Positive
(AZ = 103 / Pf = 100)
Negative
(AZ = 103 / Pf = 102)
Baseline Primary Outcome:
Baseline Booster Intention
'If you were offered [framed vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (100-point VAS)
Baseline Secondary Outcomes:
Baseline Perceived Booster Side effect Severity
'Overall, how severe do you think the [framed vaccine type] side effects are?' (100-point VAS)
Baseline Perceived Booster Risk
'What do you think the risk to your health would be if you received [framed vaccine type] as a booster vaccine, bearing in mind its side effects?' (100-point VAS)
Baseline Booster Acceptance
'Imagine that switching to the [framed vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (100-point VAS)
Manipulation: Timed presentation of framed PIL information
Post-Manipulation Primary Outcome:
Booster Intention
Post-Manipulation Secondary Outcomes:
Perceived Booster Side effect Severity
Perceived Booster Risk
Booster Acceptance
Post-Manipulation Judgement of Side Effect Prevalence
Assignment of PIL side effects to verbal risk brackets
Forced choice assignment to very common, common, uncommon, rare and very rare categories
Estimation of prevalence (X in every 100,000 individuals)
Estimation of how many people in every 100,000 affected

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may ***not be affected***)	 **Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may ***not be affected***)	 **Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

3a. Frequency of Participants by Location



3b. Demographic Information by Condition

Education by Condition



Employment by Condition



Age by Condition



4a. Booster Intention (Framing*Familiarity)



4b. Booster Intention (Framing*Familiarity*Baseline Intention)



4c. AstraZeneca Vaccine Switches



4d. Pfizer Vaccine Switch



4e. Side Effect Familiarity Ratings



Key: Framing Negative Frame Positive Frame